JNCI-Journal of the National Cancer Institute美国国家癌症研究所杂志
JNCI-Journal of the National Cancer Institute(英文缩写 JNCI-J NATL CANCER I),ISSN 0027-8874,eISSN 1460-2105,中文译名:美国国家癌症研究所杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 11.816 | Q1 |
| 2022 | 10.300 | Q1 |
| 2023 | 9.900 | Q1 |
| 2024 | 7.200 | Q1 |
| 2025 | 7.700 | Q1 |
JNCI-Journal of the National Cancer Institute 最新收录文献
-
1. Hysterectomy-corrected incidence of cervical cancer among women with HIV in the United States, 2001-2019.
1. 2001-2019年美国HIV感染女性中经子宫切除术校正的宫颈癌发病率PMID:日期:2026-10-03In the U.S., cervical cancer rates in women with HIV are notably higher than the general population. Including hysterectomized women in cervical cancer rates underestimates incidence and may misguide prevention programs. We estimated the hysterectomy-corrected incidence rates (IR) of cervical cancer among women with HIV. We used data from the HIV/AIDS Cancer Match study, linking 14 HIV and cancer registries in the US. We calculated age-standardized IRs (ASIRs) of cervical cancer before and after hysterectomy correction using hysterectomy prevalence estimates from the 2001-2019 Behavioral Risk Factor Surveillance System by age, racial/ethnic and histology. We used Poisson regression to estimate IR ratios (IRR) comparing 2005-2009, 2010-2014, and 2015-2019 to 2001-2004, adjusted for race/ethnicity, age, and region. During 2001-2019, there were 933 cervical cancer cases in 1,966,943 person-years (uncorrected ASIR 47.4 per 100,000) and 1,597,742 person-years after correction (ASIR=58.4). Hysterectomy correction increased the ASIR by 28% among Black women (50.1 vs 64.1, p < 0.0001), 18% among Hispanic women (51.7 vs 61.2, p = 0.07), and 20% among White women (30.8 vs 36.9, p = 0.26). Uncorrected ASIRs peaked at ages 40-49 and declined at older ages, while hysterectomy-corrected ASIRs remained highest at ages 40-49 but declined less with age, with similar rates among women aged 50-59 and 60-84. Compared with 2001-2004, corrected ASIRs were lower in 2005-2009 (IRR=0.79, 95%CI: 0.65,0.96); 2010-2014 (IRR=0.75, 95%CI: 0.61,0.91); and 2015-2019 (IRR=0.78, 95%CI: 0.63,0.97). Without hysterectomy correction, the most pronounced underestimation of cervical cancer ASIRs among women with HIV were observed among Black women and ≥50-year-old women.
-
2. Clonal hematopoiesis and biological aging: an interaction that increases cancer risk?
2. 克隆性造血与生物学衰老：一种增加癌症风险的相互作用？PMID:日期:2026-10-03该文献暂无摘要。
-
3. Markers of cervical intraepithelial neoplasia grade 2 regression and subsequent risk of CIN3.
3. 宫颈上皮内瘤变2级消退的标志物及随后发生CIN3的风险PMID:日期:2026-10-01Cervical intraepithelial neoplasia (CIN) grade 2 (CIN2), a precursor to cervical cancer, can regress without treatment, but the prognostic value of different regression markers remains unclear. Using electronic medical records from 5,938 women with newly detected CIN2 managed with delayed treatment at Kaiser Permanente Northern California, we estimated the frequency of histologic, cytologic, and virologic regression within 1 year of CIN2 diagnosis and the subsequent 3-year risk of CIN grade 3 or worse (CIN3+). Histologic regression was common but remained associated with appreciable subsequent CIN3+ risk. In contrast, HPV-negative results were associated with lower subsequent CIN3+ risk than normal histology or normal cytology (2.8% vs. 7.0% and 4.2%, respectively; both p < 0.001). Combined HPV-negative and normal cytology results identified the lowest risk group (1.3%; all pairwise comparisons, p < 0.001). These findings suggest that HPV clearance may be a more informative endpoint for therapeutic trials and marker for guiding surveillance of CIN2.
-
4. An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer.
4. 一种人工智能算法刻画晚期前列腺癌患者全身治疗后身体成分的恶化PMID:日期:2026-10-01Skeletal muscle is a major determinant of functional status. The impact of advanced prostate cancer (aPC) systemic therapies on body composition is unknown. We identified aPC patients with serial PET-CTs receiving androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), chemotherapy, and/or Lutetium-177. An artificial intelligence algorithm quantified body composition changes from PET-CT images. Linear mixed effects models examined body composition changes over time by treatment type. The algorithm examined 2,342 PET-CTs from 468 patients. On multivariable analysis, ADT was associated with a 9% reduction in muscle density (-1.91 Hounsfield units), ARPIs an additional 6% (-1.4 Hounsfield units), and Lutetium-177 a subsequent 6% (-1.3 Hounsfield units), demonstrating progressive reduction in muscle density across later stages of systemic therapy. This large longitudinal analysis of body composition in aPC patients supports the use of an automated PET-CT algorithm to identify aPC patients on systemic therapy at risk for muscle wasting.
-
5. Obesity and survival of Asian American and White women with breast cancer.
5. 肥胖与亚裔美国人和白人女性乳腺癌患者的生存率PMID:日期:2026-10-01It is unknown whether lower obesity in Asian American women contributes to their better survival after breast cancer (BC) diagnosis compared with non-Latina White women. In the Asian American Resiliency and Cancer (ARC) Cohort, with 3,919 Asian American and 4,978 non-Latina White women with BC, we examined associations between all-cause and BC-specific mortality, body mass index (BMI), and in a subset, waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR). Using multivariable-adjusted Cox proportional hazards regression, we estimated hazards ratios (HR) and 95% confidence intervals (CI), stratified by race/ethnicity, Asian ethnicity, menopausal status, and hormone receptor status. With 2,594 overall deaths and 1,120 BC deaths, all-cause mortality risk increased with higher BMI (per 5 kg/m2) in both Asian American (HR = 1.13, 95%CI=1.05-1.21) and non-Latina White (HR = 1.09, 95%CI=1.04-1.14) women. In the subset with abdominal adiposity measures (1,427 overall and 641 BC deaths), the range of HRs per unit increase was similar for Asian American (1.18 to 1.34) and White (1.14 to 1.19) women. For both overall and abdominal obesity, with a few exceptions, associations were observed primarily for postmenopausal women with hormone receptor-positive BC, although heterogeneity was not statistically significant. The survival difference between Asian American and non-Latina White women remained after adjustment for BMI (HR = 0.88, 95%CI=0.78-0.997). Obesity measures were not associated with BC-specific mortality, except for WHR and WHtR in Chinese women. Our findings suggest that differences in overall and abdominal obesity do not explain the BC survival differences between the two populations.
-
6. Immunotherapy-Based Therapies in Pediatric Hodgkin Lymphoma: Potential to Narrow the Gap in Long-Term Survival.
6. 儿童霍奇金淋巴瘤的免疫治疗：缩小长期生存差距的潜力PMID:日期:2026-10-01Pediatric advanced-stage Hodgkin lymphoma (HL) is highly curable, yet survivors treated with historical regimens face substantial late morbidity and excess mortality. Immunotherapy-based frontline therapies improve disease control, but late toxicities remain unknown. We developed a simulation model to project lifetime outcomes after contemporary brentuximab vedotin- or nivolumab-containing regimens using trial data (COG AHOD1331 and SWOG S1826), Childhood Cancer Survivor Study data, and national databases. We assessed how frontline and relapse therapy changes could influence long-term survival and late-effect outcomes, with sensitivity analyses to evaluate potential immunotherapy-related late mortality. Compared with expected survival at age 50 in the general population, HL survival was 86% at age 50 after historical regimens and 92-93% after contemporary immunotherapy-based therapies. Survival gains persisted unless immunotherapy-related late mortality exceeded approximately 8%. These projections suggest contemporary regimens may narrow the long-term survival gap while reducing late-effect burden.
-
7. Epstein-Barr virus-attributable cancers among children and adolescents in Europe and North America: a meta-analysis.
7. 欧洲和北美儿童及青少年中爱泼斯坦-巴尔病毒归因癌症：一项荟萃分析PMID:日期:2026-10-01Epstein-Barr virus (EBV), a common childhood infection, is associated with Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal cancer. We estimated the proportion and number of cancers attributable to EBV among individuals aged ≤19 years in Europe and North America in 2022. Embase and MEDLINE were searched from inception to August 25th, 2025. Cancer incidence was derived from GLOBOCAN. We included studies where cancer tissue from ≥8 individuals aged ≤19 years residing in Europe or North America were tested for EBV. Pooled EBV prevalence and 95% confidence intervals (CIs) were estimated using random-effects models. To obtain EBV-attributable cases, pooled prevalence was multiplied by cancer incidence. After screening 17,388 titles/abstracts and 1,084 full-texts, 53 studies met the inclusion criteria for Burkitt lymphoma (9 studies, 433 cases), Hodgkin lymphoma (40 studies, 3197 cases), and nasopharyngeal cancer (4 studies, 62 cases). The pooled prevalence of EBV was 19.7% (CI: 10.2-34.7%, I2=69.5%) in Burkitt lymphoma, 33.4% (CI: 27.4-40.0%, I2=75.6%) in Hodgkin lymphoma, and 96.8% (CI: 88.0-99.2%, I2=0.0) in nasopharyngeal cancer. An estimated 1,166 (2.8%) of 41,366 cancers diagnosed in 2022, were attributable to EBV. These cases comprised 899 Hodgkin lymphomas, 140 Burkitt lymphomas, and 127 nasopharyngeal cancers. The burden was higher among males (3.2% vs 2.3% for females) and those aged 10-14 years (5.0% vs 1.7% for 0-9-year-olds and 3.1% for 15-19-year-olds). In 2022, 2.8% of childhood cancers diagnosed in Europe and North America were attributable to EBV.
-
8. RE: Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial.
8. 回复：电针改善胃癌辅助化疗期间生活质量：一项随机试验PMID:日期:2026-09-30该文献暂无摘要。
-
9. Two-to-one randomization is associated with increased control-arm patient withdrawal.
PMID:日期:2026-09-30Patient withdrawal from a randomized clinical trial before starting the study treatment complicates the interpretation of the trial results, especially if a larger proportion patients withdraw from the control-treatment arm than the experimental-treatment arm. This may happen in an open-label trial if the patients are disappointed with their treatment assignment. It has been hypothesized that two-to-one randomization may lead to more disappointment withdrawals. To investigate this, we examined a cohort of 396 published oncology trials from four journals (2022-2025) to assess the differential pre-treatment withdrawal rates. We found that in 35 open-label trials with two-to-one randomization patients were, on average, 3.72 times more likely to withdraw on the control-treatment arm (95% CI = 2.66 to 5.22). This is a larger relative risk than was seen in the 181 open-label trials with one-to-one randomization, 1.99 (95% CI = 1.67 to 2.37). To avoid differential withdrawal, trials should be blinded when possible.